Health and Fitness Health and Fitness
Mon, February 2, 2009
Sun, February 1, 2009
Sat, January 31, 2009
Fri, January 30, 2009

Abiomed Third Fiscal Quarter 2009 Earnings and Conference Call Notification


Published on 2009-01-30 11:15:33, Last Modified on 2009-01-30 11:16:18 - Market Wire
  Print publication without navigation


DANVERS, Mass.--([ BUSINESS WIRE ])--[ Abiomed, Inc ]. (NASDAQ: ABMD) announced today that on Thursday, February 5, 2009, the Company will release third fiscal quarter 2009 results. The Company will host a conference call to discuss the results on Thursday, February 5, 2009, at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer will host the conference call.

To listen to the call live, please tune into the webcast via [ http://investor.abiomed.com ] or dial 866.356.4279; the international number is 617.597.5394. The access participant code is 37762794. A replay of this conference call will be available beginning at 10 a.m. ET on February 5, 2009 through 11:59 p.m. ET on February 19, 2009. The replay phone number is 888.286.8010; the international number is 617.801.6888. The replay access code is 72392957.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: [ www.abiomed.com ].

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recently filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

Contributing Sources